MARKET

TARS

TARS

Tarsus Pharmaceuticals, Inc.
NASDAQ
69.88
-3.14
-4.30%
Closed 16:10 03/11 EDT
OPEN
72.04
PREV CLOSE
73.02
HIGH
72.14
LOW
68.45
VOLUME
696.53K
TURNOVER
0
52 WEEK HIGH
85.25
52 WEEK LOW
38.51
MARKET CAP
2.97B
P/E (TTM)
-43.9607
1D
5D
1M
3M
1Y
5Y
1D
The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First 2026 XDEMVY Sales Outlook
Simply Wall St · 2d ago
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
TipRanks · 2d ago
Weekly Report: what happened at TARS last week (0302-0306)?
Weekly Report · 3d ago
XDEMVY Growth And China Deal Reshape Tarsus Pharmaceuticals Investment Story
Simply Wall St · 4d ago
Tarsus COO Neervannan Seshadri Disposes of Common Shares
Reuters · 6d ago
A Look At Tarsus Pharmaceuticals (TARS) Valuation After 2025 Results And New Shelf Registration
Simply Wall St · 03/02 15:17
Weekly Report: what happened at TARS last week (0223-0227)?
Weekly Report · 03/02 10:02
Tarsus Pharmaceuticals to Present at TD Cowen Annual Health Care Conference
Reuters · 02/26 21:46
More
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Webull offers Tarsus Pharmaceuticals Inc stock information, including NASDAQ: TARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARS stock methods without spending real money on the virtual paper trading platform.